Banque Transatlantique SA Buys 1,003,760 Shares of Bristol Myers Squibb Company $BMY

Key Points

• Banque Transatlantique SA significantly increased its ownership in Bristol Myers Squibb by acquiring 1,003,760 shares, raising its stake by 50,952.3%, now holding a total of 1,005,730 shares valued at approximately $56.7 million.
• Other major investors, including Wellington Management Group and GQG Partners LLC, also expanded their holdings, indicating strong institutional interest in Bristol Myers Squibb.
• Bristol Myers Squibb reported earnings of $1.46 per share for the last quarter, surpassing analyst expectations, and set a full-year EPS guidance of $6.35 to $6.65.

Banque Transatlantique SA boosted its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 50,952.3% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,005,730 shares of the biopharmaceutical company's stock after acquiring an additional 1,003,760 shares during the quarter. Bristol Myers Squibb accounts for about 1.1% of Banque Transatlantique SA's investment portfolio, making the stock its 16th largest holding. Banque Transatlantique SA's holdings in Bristol Myers Squibb were worth $56,686,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. Pinney & Scofield Inc. bought a new stake in shares of Bristol Myers Squibb during the fourth quarter valued at approximately $25,000. Park Square Financial Group LLC bought a new stake in shares of Bristol Myers Squibb in the fourth quarter worth about $26,000. Global Wealth Strategies & Associates grew its holdings in shares of Bristol Myers Squibb by 137.5% during the first quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 275 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. acquired a new position in Bristol Myers Squibb during the first quarter valued at approximately $31,000. Finally, Accent Capital Management LLC acquired a new stake in shares of Bristol Myers Squibb in the first quarter valued at approximately $33,000. 76.41% of the stock is owned by institutional investors.

Bristol Myers Squibb Stock Up 0.8%

Shares of NYSE:BMY traded up $0.39 during trading on Friday, hitting $47.08. The stock had a trading volume of 8,227,003 shares, compared to its average volume of 9,276,282. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54. Bristol Myers Squibb Company has a 12 month low of $42.96 and a 12 month high of $63.33. The company has a market capitalization of $95.84 billion, a PE ratio of 18.99, a PEG ratio of 2.41 and a beta of 0.35. The firm's fifty day moving average is $47.09 and its 200 day moving average is $50.48.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, beating the consensus estimate of $1.07 by $0.39. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The company had revenue of $12.27 billion for the quarter, compared to analyst estimates of $11.32 billion. During the same period in the previous year, the company posted $2.07 earnings per share. The firm's revenue was up .6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. Analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd were paid a $0.62 dividend. The ex-dividend date was Thursday, July 3rd. This represents a $2.48 annualized dividend and a dividend yield of 5.3%. Bristol Myers Squibb's payout ratio is currently 100.00%.

Insider Buying and Selling at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 56,000 shares of the business's stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total value of $2,650,480.00. Following the completion of the transaction, the executive vice president owned 167,379 shares in the company, valued at $7,922,048.07. The trade was a 25.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.09% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

BMY has been the subject of several research reports. Citigroup dropped their price target on Bristol Myers Squibb from $51.00 to $47.00 and set a "neutral" rating for the company in a report on Friday, August 1st. Daiwa America cut Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 5th. Daiwa Capital Markets lowered Bristol Myers Squibb from an "outperform" rating to a "neutral" rating and set a $42.00 price target for the company. in a research report on Tuesday, August 5th. Wall Street Zen downgraded Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a research note on Friday, June 6th. Finally, Morgan Stanley reiterated a "hold" rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $56.38.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.